Covid-19 Drug Research: Chinese Study Shows That Antimalarial Drug Hydroxychloroquine No Better Than Standard Care

Covid-19 Drug Research: A study conducted by researchers from the Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai has shown that Hydroxychloroquine, an antimalarial drug dubbed a “gift from God” by US President Donald Trump for its potential ability to fight the Covid-19 disease, was found to be no more effective than standard treatment in the small study.

The Covid-19 Drug research paper  in the Journal of Zhejiang University on March 6. http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03 and also http://subject.med.wanfangdata.com.cn/UpLoad/Files/202003/43f8625d4dc74e42bbcf24795de1c77c.pdf

The drug research study looked at 30 COVID-19 patients, half of whom received the medicine. After seven days, 13 of the patients who were on the drug tested negative, compared to 14 people who weren’t on it.

Significantly, one of the patients on it went on to develop severe illness, while the median time taken for the individuals to recover was similar in both groups.

It should be noted that the sample size is considered too small to be statistically significant.

However a similar number of patients were examined in a recent French study that found the same drug to be highly effective at fighting the infection, especially when taken in combination with the antibiotic azithromycin.( https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf) …

https://www.thailandmedical.news/news/covid-19-drug-research-chinese-study-shows-that-antimalarial-drug-hydroxychloroquine-no-better-than-standard-covid-19-care

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.